Qiming U.S. Healthcare Fund II, L.P. - 27 Jan 2023 Form 4 Insider Report for Jasper Therapeutics, Inc. (JSPR)

Reporting relationship: 10%+ Owner
Issuer ticker: JSPR
Reported as of: 27 Jan 2023
Net transaction value: +$3,999,999
SEC form: 4
Accepted by SEC: 11 Apr 2023, 19:55:00 UTC
Prior SEC filing: 01 Oct 2021
Source filing: View source filing
Reporting owner signature: Qiming U.S. Healthcare Fund II, L.P., By: Qiming U.S. Healthcare GP II, LLC, its general partner, By /s/ Mark McDade, Managing Partner

Key filing fact

Qiming U.S. Healthcare Fund II, L.P. filed Form 4 for Jasper Therapeutics, Inc. (JSPR) on 11 Apr 2023.

Key facts

This page summarizes Qiming U.S. Healthcare Fund II, L.P.'s Form 4 filing for Jasper Therapeutics, Inc. (JSPR).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 11 Apr 2023, 19:55.

Change

Previous filing in this sequence was filed on 01 Oct 2021.
Current net transaction value: +$3,999,999.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

JSPR transaction

Voting Common Stock

Purchase

Transaction value: $3,999,999
Shares: +2,666,666
Change %: +46%
Price: $1.50
Shares after: 8,519,648
Date: 27 Jan 2023
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Qiming U.S. Healthcare Fund II, L.P. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 1 footnote

Footnote F1

The securities are directly held by Qiming U.S. Healthcare Fund II, L.P. ("Qiming"). The general partner of Qiming is Qiming U.S. Healthcare GP II, LLC ("Qiming GP"). Gary Rieschel and Mark McDade are the managing partners of Qiming GP and may be deemed to share voting and dispositive power over the shares held by Qiming. Each of Qiming GP and Messrs. Rieschel and McDade disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein.